The #1 Energy Stock to Buy
The next major energy revolution is unfolding right now. And it could hand early investors as much as 46,700% gains…
Get the Name & Ticker Here

CING Insider Trading

Insider Ownership Percentage: 31.28%
Insider Buying (Last 12 Months): $358,177.03
Insider Selling (Last 12 Months): $22,265.64

Cingulate Insider Trading History Chart

This chart shows the insider buying and selling history at Cingulate by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Cingulate Share Price & Price History

Current Price: $1.01
Price Change: Price Increase of +0.02 (2.02%)
As of 02/6/2023 06:19 PM ET

This chart shows the closing price history over time for CING up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365

Cingulate Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/16/2022Shane J SchafferCEOBuy10,000$1.02$10,200.0041,500View SEC Filing Icon  
12/14/2022Jennifer L CallahanInsiderBuy7,548$0.99$7,472.5234,508View SEC Filing Icon  
12/13/2022Peter J WerthDirectorBuy28,934$0.98$28,355.32975,165View SEC Filing Icon  
12/13/2022Shane J SchafferCEOBuy1,733$1.01$1,750.3318,233View SEC Filing Icon  
11/28/2022Jennifer L CallahanInsiderBuy3,487$0.98$3,417.2625,430View SEC Filing Icon  
11/23/2022Craig S GilgallonEVPBuy3,575$0.84$3,003.009,550View SEC Filing Icon  
11/23/2022Laurie MyersCOOBuy1,111$0.90$999.9048,263View SEC Filing Icon  
11/22/2022Gregg Wm GivensDirectorBuy85,000$0.88$74,800.00154,318View SEC Filing Icon  
9/8/2022Jennifer L CallahanInsiderBuy3,500$1.50$5,250.0021,943View SEC Filing Icon  
9/6/2022Peter J WerthDirectorBuy74,500$1.52$113,240.00946,231View SEC Filing Icon  
6/1/2022Laurie MyersCOOBuy200$1.18$236.0046,716View SEC Filing Icon  
5/17/2022Laurie MyersCOOBuy200$1.21$242.0046,516View SEC Filing Icon  
5/6/2022Curtis MedeirosDirectorSell17,532$1.27$22,265.64View SEC Filing Icon  
3/17/2022Peter J WerthDirectorBuy27,000$1.79$48,330.00View SEC Filing Icon  
3/16/2022Jennifer L CallahanInsiderBuy1,900$1.39$2,641.00View SEC Filing Icon  
3/16/2022Laurie MyersCOOBuy353$1.40$494.20View SEC Filing Icon  
3/14/2022Craig S GilgallonEVPBuy5,975$1.38$8,245.50View SEC Filing Icon  
3/14/2022Gregg Wm GivensDirectorBuy9,000$1.32$11,880.00View SEC Filing Icon  
3/14/2022Horn Louis G VanCFOBuy15,000$1.34$20,100.00View SEC Filing Icon  
3/14/2022Jennifer L CallahanInsiderBuy12,000$1.46$17,520.00View SEC Filing Icon  
See Full Table

SEC Filings (Institutional Ownership Changes) for Cingulate (NASDAQ:CING)

2.35% of Cingulate stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at CING by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table

Cingulate Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
11/8/2022Eagle Asset Management Inc.107,527$0.12M0.0%+124.5%0.951%Search for SEC Filing on Google Icon
8/16/2022Creative Planning23,510$34K0.0%N/A0.208%Search for SEC Filing on Google Icon
8/13/2022Renaissance Technologies LLC44,600$65K0.0%-12.5%0.394%Search for SEC Filing on Google Icon
5/13/2022Renaissance Technologies LLC51,000$100K0.0%N/A0.451%Search for SEC Filing on Google Icon
5/12/2022Eagle Asset Management Inc.47,895$94K0.0%N/A0.424%Search for SEC Filing on Google Icon
5/5/2022Lynwood Capital Management Inc.225,994$0.45M0.5%+80.8%1.998%Search for SEC Filing on Google Icon
2/14/2022Altium Capital Management LP83,931$0.23M0.1%N/A0.742%Search for SEC Filing on Google Icon
Data available starting January 2016

See Full Table
Cingulate logo
Cingulate Inc., a clinical-stage biopharmaceutical company, focuses on the development of product candidates for the treatment of attention-deficit/hyperactivity disorder. The company's lead product candidates are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, and CTx-1302 (dextroamphetamine) for the treatment of attention-deficit/hyperactivity disorders. It also focuses on developing CTx-2103 for the treatment of anxiety disorders. The company was founded in 2012 and is headquartered in Kansas City, Kansas.
Read More on Cingulate

Today's Range

Now: $1.01
Low: $0.95
High: $1.01

50 Day Range

MA: $0.97
Low: $0.89
High: $1.08

52 Week Range

Now: $1.01
Low: $0.66
High: $2.20

Volume

21,097 shs

Average Volume

47,683 shs

Market Capitalization

$11.42 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.31

Who are the company insiders with the largest holdings of Cingulate?

Cingulate's top insider investors include:
  1. Peter J Werth (Director)
  2. Gregg Wm Givens (Director)
  3. Laurie Myers (COO)
  4. Shane J Schaffer (CEO)
  5. Jennifer L Callahan (Insider)
  6. Craig S Gilgallon (EVP)
  7. Curtis Medeiros (Director)
  8. Horn Louis G Van (CFO)
Learn More about top insider investors at Cingulate.
The #1 Energy Stock to Buy
The next major energy revolution is unfolding right now. And it could hand early investors as much as 46,700% gains…
Get the Name & Ticker Here